The results
The AMBAR trial has demonstrated a significant reduction in the progression of Alzheimer's in moderate patients.
AMBAR, an innovative treatment approach for Alzheimer's disease (AD) based on the combination of Plasmapheresis with Albutein® 20% replacement under development in phase IIb/III, may offer a new treatment pathway for the illness in the future.
Press release
AMBAR in the media:
Alzheimer's Disease
It is currently estimated that 35 million people worldwide suffer from Alzheimer's, and this figure is continuing to grow.
Grifols and Alzheimer's
Since 2004, we have led a broad range of research initiatives on Alzheimer's.
The AMBAR hypothesis
AMBAR is an innovative treatment proposal aimed at slowing the progression of Alzheimer's disease through periodic plasma exchange.
The AMBAR
study
AMBAR is an international and multicenter clinical trial designed by Grifols in collaboration with Fundació ACE in Barcelona, Spain; and the Alzheimer Disease Research Center in Pittsburgh, PA, U.S.